Physician profile

Ramez Haddadin

Ophthalmology · Chicago, IL

NPI 1447486329

$6,482.70

in general payments reported to CMS, 2019-2025

3 companies · $2,250 in 2025

The $2,250 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$2,250.00
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$2,250.00
Travel and Lodging$1,087.30

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alcon Vision LLC $5,682.70 2019-2025
Johnson & Johnson Surgical Vision, INC. $800.00 2019

1 company reported research payments only; those appear in the research section below.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ramez Haddadin

$6,482.70

in general payments reported 2019-2025

Years
2019-2025
Top company
Alcon Vision LLC
Context
The $2,250 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).

https://glasscript.com/doctor/916686/ramez-haddadin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.